SARS-CoV-2 (COVID-19) Nucleocapsid antibody

A Clinical-Stage Cysteine Protease Inhibitor blocks SARS-CoV-2 Infection of Human and Monkey Cells. Mellott DM et al., 2021 Apr 16, ACS Chem Biol

Convergent antibody responses to SARS-CoV-2 in convalescent individuals. Robbiani DF et al., 2020 Aug, Nature

Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Robbiani DF et al., 2020 May 22, bioRxiv

COVID-19 vaccine mRNA-1273 elicits a protective immune profile in mice that is not associated with vaccine-enhanced disease upon SARS-CoV-2 challenge. DiPiazza AT et al., 2021 Aug 10, Immunity

Enhanced SARS-CoV-2 Neutralization by Secretory IgA in vitro. Wang Z et al., 2020 Sep 9, bioRxiv

Evaluation of the mRNA-1273 Vaccine against SARS-CoV-2 in Nonhuman Primates. Corbett KS et al., 2020 Oct 15, N Engl J Med

Genome-scale identification of SARS-CoV-2 and pan-coronavirus host factor networks. Schneider WM et al., 2020 Oct 8, bioRxiv

Immune correlates of protection by mRNA-1273 vaccine against SARS-CoV-2 in nonhuman primates. Corbett KS et al., 2021 Sep 17, Science

In vitro and in vivo functions of SARS-CoV-2 infection-enhancing and neutralizing antibodies. Li D et al., 2021 Aug 5, Cell

Interactions of SARS-CoV-2 envelope protein with amilorides correlate with antiviral activity. Park SH et al., 2021 May, PLoS Pathog